Atrophy of the cholinergic regions advances from early to late mild cognitive impairment
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
PURPOSE: We investigated the volumetric changes in the components of the cholinergic pathway for patients with early mild cognitive impairment (EMCI) and those with late mild cognitive impairment (LMCI). The effect of patients' apolipoprotein 4 (APOE-ε4) allele status on the structural changes were analyzed.
METHODS: Structural magnetic resonance imaging data were collected. Patients' demographic information, plasma data, and validated global cognitive composite scores were included. Relevant features were extracted for constructing machine learning models to differentiate between EMCI (n = 312) and LMCI (n = 541) and predict patients' neurocognitive function. The data were analyzed primarily through one-way analysis of variance and two-way analysis of covariance.
RESULTS: Considerable differences were observed in cholinergic structural changes between patients with EMCI and LMCI. Cholinergic atrophy was more prominent in the LMCI cohort than in the EMCI cohort (P < 0.05 family-wise error corrected). APOE-ε4 differentially affected cholinergic atrophy in the LMCI and EMCI cohorts. For LMCI cohort, APOE-ε4 carriers exhibited increased brain atrophy (left amygdala: P = 0.001; right amygdala: P = 0.006, and right Ch123, P = 0.032). EMCI and LCMI patients showed distinctive associations of gray matter volumes in cholinergic regions with executive (R2 = 0.063 and 0.030 for EMCI and LMCI, respectively) and language (R2 = 0.095 and 0.042 for EMCI and LMCI, respectively) function.
CONCLUSIONS: Our data confirmed significant cholinergic atrophy differences between early and late stages of mild cognitive impairment. The impact of the APOE-ε4 allele on cholinergic atrophy varied between the LMCI and EMCI groups.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Neuroradiology - 66(2024), 4 vom: 04. März, Seite 543-556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lai, Ying-Liang Larry [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
APOE-ε4 allele |
|---|
| Anmerkungen: |
Date Completed 14.03.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00234-024-03290-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367312581 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367312581 | ||
| 003 | DE-627 | ||
| 005 | 20240314234920.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00234-024-03290-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1329.xml |
| 035 | |a (DE-627)NLM367312581 | ||
| 035 | |a (NLM)38240769 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lai, Ying-Liang Larry |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atrophy of the cholinergic regions advances from early to late mild cognitive impairment |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2024 | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a PURPOSE: We investigated the volumetric changes in the components of the cholinergic pathway for patients with early mild cognitive impairment (EMCI) and those with late mild cognitive impairment (LMCI). The effect of patients' apolipoprotein 4 (APOE-ε4) allele status on the structural changes were analyzed | ||
| 520 | |a METHODS: Structural magnetic resonance imaging data were collected. Patients' demographic information, plasma data, and validated global cognitive composite scores were included. Relevant features were extracted for constructing machine learning models to differentiate between EMCI (n = 312) and LMCI (n = 541) and predict patients' neurocognitive function. The data were analyzed primarily through one-way analysis of variance and two-way analysis of covariance | ||
| 520 | |a RESULTS: Considerable differences were observed in cholinergic structural changes between patients with EMCI and LMCI. Cholinergic atrophy was more prominent in the LMCI cohort than in the EMCI cohort (P < 0.05 family-wise error corrected). APOE-ε4 differentially affected cholinergic atrophy in the LMCI and EMCI cohorts. For LMCI cohort, APOE-ε4 carriers exhibited increased brain atrophy (left amygdala: P = 0.001; right amygdala: P = 0.006, and right Ch123, P = 0.032). EMCI and LCMI patients showed distinctive associations of gray matter volumes in cholinergic regions with executive (R2 = 0.063 and 0.030 for EMCI and LMCI, respectively) and language (R2 = 0.095 and 0.042 for EMCI and LMCI, respectively) function | ||
| 520 | |a CONCLUSIONS: Our data confirmed significant cholinergic atrophy differences between early and late stages of mild cognitive impairment. The impact of the APOE-ε4 allele on cholinergic atrophy varied between the LMCI and EMCI groups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a APOE-ε4 allele | |
| 650 | 4 | |a Early mild cognitive impairment (EMCI) | |
| 650 | 4 | |a cholinergic pathway | |
| 650 | 4 | |a mild cognitive impairment (MCI) | |
| 650 | 4 | |a nucleus basalis of Meynert | |
| 650 | 7 | |a Cholinergic Agents |2 NLM | |
| 650 | 7 | |a Apolipoproteins E |2 NLM | |
| 700 | 1 | |a Hsu, Fei-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Yeh, Shu-Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Yu-Tzu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Hui-Hsien |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yi-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Kuo, Li-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Cheng-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hua-Shan |e verfasserin |4 aut | |
| 700 | 0 | |a Alzheimer’s Disease Neuroimaging Initiative |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroradiology |d 1971 |g 66(2024), 4 vom: 04. März, Seite 543-556 |w (DE-627)NLM000263672 |x 1432-1920 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2024 |g number:4 |g day:04 |g month:03 |g pages:543-556 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00234-024-03290-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2024 |e 4 |b 04 |c 03 |h 543-556 | ||